NCT04218305

Brief Summary

The aim of this study is to assess the significance of serum fetuin-A as a marker of obesity and type 2 diabetes mellitus. We used multiple statistical approaches to determine that the fetuin-A level is correlated to body mass index (BMI) as well as random blood sugar in type 2 diabetic patients. Also, we found that there is a Positive correlation between the serum fetuin-A levels and the level of glycosylated hemoglobin (HbA1c) in diabetic patients.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2016

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

January 2, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 6, 2020

Completed
Last Updated

January 6, 2020

Status Verified

January 1, 2020

Enrollment Period

1 month

First QC Date

January 2, 2020

Last Update Submit

January 2, 2020

Conditions

Diabete Type 2

Outcome Measures

Primary Outcomes (1)

  • 1- Study of human serum fetuin-A and whether it is involved in insulin resistance

    2- To assess the significance of serum fetuin-A as a marker in obesity and type 2 diabetes mellitus

    Baesline

Study Arms (4)

The first group

Include One hundred patients with type 2 diabetes mellitus with average body mass index.

Diagnostic Test: Serum Level Of Fetuin A

The second group

Include One hundred patients whose body mass index is 30 or over without diabetes.

Diagnostic Test: Serum Level Of Fetuin A

The third group

Include One hundred type 2 diabetic obese patients whose body mass index is 30 or over.

Diagnostic Test: Serum Level Of Fetuin A

The fourth group

Include One hundred apparently healthy adult person as a control.

Diagnostic Test: Serum Level Of Fetuin A

Interventions

Serum Level Of Fetuin ADIAGNOSTIC_TEST
The first groupThe fourth groupThe second groupThe third group

Eligibility Criteria

Age45 Years - 60 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

You may qualify if:

  • The study included obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

You may not qualify if:

  • Cardiac disease and Hypertensive disease
  • Respiratory disease
  • Renal disease
  • GIT and Liver disease
  • Rheumatologic disease
  • Blood disease
  • Endocrine disease except for type 2 diabetes mellitus
  • All with a specific therapeutic drug history.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

January 2, 2020

First Posted

January 6, 2020

Study Start

January 1, 2016

Primary Completion

February 1, 2016

Study Completion

March 1, 2016

Last Updated

January 6, 2020

Record last verified: 2020-01